Get the Stockscreener App
0.5168
0.67%
-0.0035
After Hours:
.50
-0.0168
-3.25%
Citius Pharmaceuticals Inc stock is traded at $0.5168, with a volume of 177.95K.
It is down -0.67% in the last 24 hours and down -4.30% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
See More
Previous Close:
$0.5203
Open:
$0.5
24h Volume:
177.95K
Relative Volume:
0.29
Market Cap:
$14.19M
Revenue:
$5.61M
Net Income/Loss:
$-55.45M
P/E Ratio:
-0.2011
EPS:
-2.5703
Net Cash Flow:
$-42.35M
1W Performance:
+7.53%
1M Performance:
-4.30%
6M Performance:
-37.55%
1Y Performance:
-69.05%
1-Day Range:
$0.4903
$0.5395
1-Week Range:
$0.4903
$0.60
52-Week Range:
$0.4687
$2.19
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.5168 | 14.28M | 5.61M | -55.45M | -42.35M | -2.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Upgrade | D. Boral Capital | Hold → Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
CTXR|Citius Pharmaceuticals Inc|Price:0.531|Chg%:+0.010 - TradingKey
Citius Pharmaceuticals Inc (CTXR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Pharmaceuticals Inc (CTXR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
CTXR|Citius Pharmaceuticals Inc|Price:0.520|Chg%:-0.011 - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey
Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary - Quartr
Citius Oncology expands sales team for LYMPHIR launch By Investing.com - Investing.com South Africa
Citius Oncology expands sales team for LYMPHIR launch - Investing.com
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - Morningstar
Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
Citius Oncology (CTOR) Registration filing Summary - Quartr
Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals (CTXR) Edges Lower, Testing Key Support at $0.51IV Crush Alert - dars.gov.et
Enterprise value to revenue forward of Citius Pharmaceuticals Inc – LS:A40MD0 - TradingView
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Pharmaceuticals updates pipeline as investors track CTXR stock - Ad-hoc-news.de
Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is A Biotech Runner: Here's Why - Insider Financial
Citius Pharmaceuticals Q4 2025 Earnings: EPS Miss Exceeds 45% as Pre-Revenue Biotech Navigates Clinical MilestonesAdjusted Earnings Analysis - DonanımHaber
A40MD0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Price to earnings forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
47N0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBITDA forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals Inc Actuals & Estimates (FWB:47N0) - TradingView
Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBITDA forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Citius Pharmaceuticals Inc Actuals & Estimates (NASDAQ:CTXR) - TradingView
CTXR Forecast — Price Target — Prediction for 2027 - TradingView
Citius Pharmaceuticals updates I/ ONTAK launch progress, shares trade on Nasdaq - AD HOC NEWS
Citius Pharmaceuticals Inc (CTXR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Citius Pharmaceuticals (CTXR) price target increased by 20.00% to 6.12 - MSN
Citius Pharmaceuticals Inc (CTXR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Citius Pharmaceuticals Inc (CTXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Pharmaceuticals Inc (CTXR) Institutional Confidence - TradingKey
Citius Pharmaceuticals Inc (CTXR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan
Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan
[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks
Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
Citius Oncology (NASDAQ: CTXR) shares early Phase 1 LYMPHIR cancer data - Stock Titan
Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - BioSpace
Citius Oncology presents study data on LYMPHIR combination By Investing.com - Investing.com Australia
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):